Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin

W. T. Stephenson, S. M. Poirier, L. Rubin, Lawrence Einhorn

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Purpose: To evaluate the infertility rate in patients with germ cell tumors receiving chemotherapy with cisplatin, etoposide (VP-16), and bleomycin (PVP16B). Patients and Methods: Thirty patients were evaluated. All patients had undergone chemotherapy with two to four cycles of PVP16B. A single semen analysis was performed 24 to 78 months following initiation of chemotherapy. All 30 patients were continuously disease-free. Eight of these patients had also undergone nerve-sparing retroperitoneal lymph node dissection (RPLND). Results: The median sperm concentration was 33.9 x 106, with a median volume of 3.2 mL. The median total sperm count was 86.4 x 106. Oligospermia (< 40 x 106 total sperm count) was found in 13 patients (43%), including six (20%) who were azoospermic. There was a high incidence of morphologically abnormal sperm, with only one patient having more than 50% normal spermatozoa. Only 13 patients (43%) had sperm motility greater than 50%. Five patients had positive semen antisperm immunoglobulin G (IgG). Eight patients fathered children, including three with documented oligospermia. Conclusion: Patients with germ cell tumors successfully treated with PVP16B chemotherapy are at substantial risk for persistent semen abnormalities. However, some patients with oligospermia will slowly recover and others are still capable of reproductive capacity despite continued oligospermia.

Original languageEnglish
Pages (from-to)2278-2280
Number of pages3
JournalJournal of Clinical Oncology
Volume13
Issue number9
StatePublished - 1995

Fingerprint

Germ Cell and Embryonal Neoplasms
Bleomycin
Etoposide
Cisplatin
Oligospermia
Therapeutics
Spermatozoa
Drug Therapy
Sperm Count
Semen
Semen Analysis
Sperm Motility
Lymph Node Excision
Infertility
Immunoglobulin G

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin. / Stephenson, W. T.; Poirier, S. M.; Rubin, L.; Einhorn, Lawrence.

In: Journal of Clinical Oncology, Vol. 13, No. 9, 1995, p. 2278-2280.

Research output: Contribution to journalArticle

@article{f53a094667884519844061d5bf3e348d,
title = "Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin",
abstract = "Purpose: To evaluate the infertility rate in patients with germ cell tumors receiving chemotherapy with cisplatin, etoposide (VP-16), and bleomycin (PVP16B). Patients and Methods: Thirty patients were evaluated. All patients had undergone chemotherapy with two to four cycles of PVP16B. A single semen analysis was performed 24 to 78 months following initiation of chemotherapy. All 30 patients were continuously disease-free. Eight of these patients had also undergone nerve-sparing retroperitoneal lymph node dissection (RPLND). Results: The median sperm concentration was 33.9 x 106, with a median volume of 3.2 mL. The median total sperm count was 86.4 x 106. Oligospermia (< 40 x 106 total sperm count) was found in 13 patients (43{\%}), including six (20{\%}) who were azoospermic. There was a high incidence of morphologically abnormal sperm, with only one patient having more than 50{\%} normal spermatozoa. Only 13 patients (43{\%}) had sperm motility greater than 50{\%}. Five patients had positive semen antisperm immunoglobulin G (IgG). Eight patients fathered children, including three with documented oligospermia. Conclusion: Patients with germ cell tumors successfully treated with PVP16B chemotherapy are at substantial risk for persistent semen abnormalities. However, some patients with oligospermia will slowly recover and others are still capable of reproductive capacity despite continued oligospermia.",
author = "Stephenson, {W. T.} and Poirier, {S. M.} and L. Rubin and Lawrence Einhorn",
year = "1995",
language = "English",
volume = "13",
pages = "2278--2280",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin

AU - Stephenson, W. T.

AU - Poirier, S. M.

AU - Rubin, L.

AU - Einhorn, Lawrence

PY - 1995

Y1 - 1995

N2 - Purpose: To evaluate the infertility rate in patients with germ cell tumors receiving chemotherapy with cisplatin, etoposide (VP-16), and bleomycin (PVP16B). Patients and Methods: Thirty patients were evaluated. All patients had undergone chemotherapy with two to four cycles of PVP16B. A single semen analysis was performed 24 to 78 months following initiation of chemotherapy. All 30 patients were continuously disease-free. Eight of these patients had also undergone nerve-sparing retroperitoneal lymph node dissection (RPLND). Results: The median sperm concentration was 33.9 x 106, with a median volume of 3.2 mL. The median total sperm count was 86.4 x 106. Oligospermia (< 40 x 106 total sperm count) was found in 13 patients (43%), including six (20%) who were azoospermic. There was a high incidence of morphologically abnormal sperm, with only one patient having more than 50% normal spermatozoa. Only 13 patients (43%) had sperm motility greater than 50%. Five patients had positive semen antisperm immunoglobulin G (IgG). Eight patients fathered children, including three with documented oligospermia. Conclusion: Patients with germ cell tumors successfully treated with PVP16B chemotherapy are at substantial risk for persistent semen abnormalities. However, some patients with oligospermia will slowly recover and others are still capable of reproductive capacity despite continued oligospermia.

AB - Purpose: To evaluate the infertility rate in patients with germ cell tumors receiving chemotherapy with cisplatin, etoposide (VP-16), and bleomycin (PVP16B). Patients and Methods: Thirty patients were evaluated. All patients had undergone chemotherapy with two to four cycles of PVP16B. A single semen analysis was performed 24 to 78 months following initiation of chemotherapy. All 30 patients were continuously disease-free. Eight of these patients had also undergone nerve-sparing retroperitoneal lymph node dissection (RPLND). Results: The median sperm concentration was 33.9 x 106, with a median volume of 3.2 mL. The median total sperm count was 86.4 x 106. Oligospermia (< 40 x 106 total sperm count) was found in 13 patients (43%), including six (20%) who were azoospermic. There was a high incidence of morphologically abnormal sperm, with only one patient having more than 50% normal spermatozoa. Only 13 patients (43%) had sperm motility greater than 50%. Five patients had positive semen antisperm immunoglobulin G (IgG). Eight patients fathered children, including three with documented oligospermia. Conclusion: Patients with germ cell tumors successfully treated with PVP16B chemotherapy are at substantial risk for persistent semen abnormalities. However, some patients with oligospermia will slowly recover and others are still capable of reproductive capacity despite continued oligospermia.

UR - http://www.scopus.com/inward/record.url?scp=0029163004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029163004&partnerID=8YFLogxK

M3 - Article

C2 - 7545220

AN - SCOPUS:0029163004

VL - 13

SP - 2278

EP - 2280

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -